AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
5,815.00GBp
18 Apr 2019
5,815.00GBp
18 Apr 2019
Change (% chg)
-99.00 (-1.67%)
-99.00 (-1.67%)
Prev Close
5,914.00
5,914.00
Open
5,860.00
5,860.00
Day's High
5,894.00
5,894.00
Day's Low
5,806.00
5,806.00
Volume
2,072,049
2,072,049
Avg. Vol
2,159,553
2,159,553
52-wk High
6,540.00
6,540.00
52-wk Low
4,928.50
4,928.50
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Dec '18 | 6,417.00 | 0.816 |
| Sep '18 | 5,340.00 | 0.340 | |
| Jun '18 | 5,155.00 | 0.276 | |
| Mar '18 | 5,178.00 | 0.268 | |
| FY 2017 | Dec '17 | 5,777.00 | 1.048 |
| Sep '17 | 6,232.00 | 0.541 | |
| Jun '17 | 5,051.00 | 0.376 | |
| Mar '17 | 5,405.00 | 0.424 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 8 | 5,624.77 | 5,775.00 | 5,460.00 | 5,527.68 |
| Quarter Ending Sep-19 | 8 | 5,967.53 | 6,187.00 | 5,725.50 | 6,197.14 |
| Year Ending Dec-19 | 24 | 23,517.90 | 24,393.00 | 22,578.00 | 23,948.40 |
| Year Ending Dec-20 | 26 | 25,965.40 | 28,421.00 | 24,249.40 | 26,274.30 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 7 | 0.76 | 0.82 | 0.70 | 1.04 |
| Quarter Ending Sep-19 | 7 | 0.97 | 1.08 | 0.85 | 0.94 |
| Year Ending Dec-19 | 26 | 3.59 | 4.16 | 3.21 | 3.97 |
| Year Ending Dec-20 | 26 | 4.31 | 5.14 | 3.46 | 4.83 |
| LT Growth Rate (%) | 3 | 12.48 | 19.60 | 3.75 | 5.21 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 22.12 | 29.30 | 32.55 | |
| P/E High - Last 5 Yrs. | 72.73 | 43.17 | 48.10 | |
| P/E Low - Last 5 Yrs. | 9.58 | 22.71 | 23.42 | |
| Beta | 1.04 | 0.86 | 0.87 | |
| Price to Sales (TTM) | 3.94 | 6.59 | 8.39 | |
| Price to Book (MRQ) | 6.27 | 5.12 | 5.27 | |
| Price to Tangible Book (MRQ) | -- | 5.84 | 6.74 | |
| Price to Cash Flow (TTM) | 13.70 | 23.07 | 24.13 | |
| % Owned Institutions | -- | 0.87 | 1.65 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.43 | 1.35 | |
| Dividend Yield - 5 Year Avg | 5.55 | 1.45 | 1.37 | |
| Dividend 5 Year Growth Rate | 4.86 | 3.99 | 4.70 | |
| Payout Ratio(TTM) | 62.12 | 42.19 | 39.61 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -9.85 | 5.43 | 13.46 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -9.65 | 6.61 | 8.04 | |
| Sales - 5 Yr. Growth Rate | -7.29 | 10.48 | 10.85 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 15,985.23 | 45.67 | 47.73 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 74.09 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -17.55 | 9.90 | 10.46 | |
| Capital Spending - 5 Yr. Growth Rate | 12.28 | 15.26 | 14.68 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.73 | 2.07 | 2.18 |
| Current Ratio (MRQ) | 0.91 | 2.87 | 2.98 |
| LT Debt to Equity (MRQ) | 122.99 | 8.87 | 11.32 |
| Total Debt to Equity (MRQ) | 144.47 | 12.86 | 16.01 |
| Interest Coverage (TTM) | 4.61 | 32.48 | 28.44 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 82.88 | 52.10 | 52.41 | |
| Gross Margin - 5 Yr. Avg. | 80.69 | 49.66 | 50.39 | |
| EBITD Margin (TTM) | 38.95 | -- | -- | |
| EBITD - 5 Yr. Avg | 31.99 | 17.26 | 12.41 | |
| Operating Margin (TTM) | 24.85 | 13.53 | 5.77 | |
| Operating Margin - 5 Yr. Avg. | 17.97 | 13.69 | 8.01 | |
| Pre-Tax Margin (TTM) | 18.09 | 11.88 | 4.79 | |
| Pre-Tax Margin - 5 Yr. Avg. | 14.67 | 14.09 | 8.29 | |
| Net Profit Margin (TTM) | 17.34 | 8.79 | 1.52 | |
| Net Profit Margin - 5 Yr. Avg. | 12.74 | 10.58 | 4.70 | |
| Effective Tax Rate (TTM) | 4.14 | 22.12 | 22.13 | |
| Effective Tax Rate - 5 Yr. Avg. | 13.16 | 22.26 | 22.58 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 278,767 | 928,597,997 | 820,413,093 | |
| Net Income/Employee (TTM) | 48,342 | 105,162,136 | 92,866,243 | |
| Receivable Turnover (TTM) | 4.36 | 5.84 | 5.82 | |
| Inventory Turnover (TTM) | 1.40 | 2.57 | 3.41 | |
| Asset Turnover (TTM) | 0.34 | 0.93 | 0.90 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 5.82 | 10.98 | 10.60 | |
| Return on Assets - 5 Yr. Avg. | 5.71 | 12.41 | 11.78 | |
| Return on Investment (TTM) | 7.86 | 14.23 | 13.83 | |
| Return on Investment - 5 Yr. Avg. | 7.89 | 16.18 | 15.32 | |
| Return on Equity (TTM) | 28.47 | 15.46 | 15.25 | |
| Return on Equity - 5 Yr. Avg. | 15.71 | 17.07 | 16.41 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -6.90 | -3.76 | -7.29 |
| EPS (TTM) % | 23.76 | 10.68 | -17.55 |
| Dividend % | 26.80 | 8.24 | 4.86 |
Note: Units in Millions of US Dollars
Performance for AstraZeneca PLC
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 7.60 | 5.39 | 99 | 29 |
| 13 Week | 0.47 | -2.14 | 99 | 42 |
| 26 Week | 7.52 | 4.45 | 99 | 44 |
| 52 Week | 2.55 | -5.39 | 99 | 11 |
| YTD | 16.15 | 8.98 | 99 | 38 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- UPDATE 2-European shares rise as short covering, earnings help temper tepid PMIs
- FTSE 100 dips on sluggish euro zone PMI, Unilever sparkles
- UPDATE 2-FTSE 100 dips on sluggish euro zone PMI, Unilever sparkles
- Banks, pharma drag FTSE 100 but Unilever cheery on strong quarter
- London's shares off six-month highs, Bunzl suffers worst day in a decade
Institutional Holders
| % Shares Owned: | 57.62% |
| # of Holders: | 599 |
| Total Shares Held: | 755,826,947 |
| 3 Mo. Net Change: | -3,911,850 |
| # New Positions: | 12 |
| # Closed Positions: | 12 |
| # Increased Positions: | 97 |
| # Reduced Positions: | 121 |
| # Net Buyers: | -24 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks